MXPA05007466A - Metodos para el tratamiento de enfermedades pulmonares. - Google Patents
Metodos para el tratamiento de enfermedades pulmonares.Info
- Publication number
- MXPA05007466A MXPA05007466A MXPA05007466A MXPA05007466A MXPA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lung diseases
- treating lung
- ligand
- oropharyngeal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
La presente invencion describe composiciones y metodos para el tratamiento de enfermedades pulmonares. En las modalidades preferidas, los metodos involucran la administracion al sujeto via una ruta pulmonar, orofaringea o nasofaringea, de un compuesto o composicion que contiene un agente terapeutico y un elemento objetivo dirigido a un ligando. El ligando es preferiblemente un epitope en el receptor pIgR.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43937303P | 2003-01-09 | 2003-01-09 | |
US48004703P | 2003-06-20 | 2003-06-20 | |
US49484103P | 2003-08-12 | 2003-08-12 | |
PCT/US2004/000445 WO2004062603A2 (en) | 2003-01-09 | 2004-01-09 | Methods of treating lung diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05007466A true MXPA05007466A (es) | 2006-03-08 |
Family
ID=32719208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05007466A MXPA05007466A (es) | 2003-01-09 | 2004-01-09 | Metodos para el tratamiento de enfermedades pulmonares. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050036951A1 (es) |
EP (1) | EP1589943A2 (es) |
KR (1) | KR20050114211A (es) |
AU (1) | AU2004204764A1 (es) |
CA (1) | CA2512672A1 (es) |
IL (1) | IL169602A0 (es) |
MX (1) | MXPA05007466A (es) |
WO (1) | WO2004062603A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101421621A (zh) * | 2004-02-17 | 2009-04-29 | 比南股份有限公司 | 检测多种病原体的方法和试剂盒 |
WO2006060051A2 (en) * | 2004-09-13 | 2006-06-08 | Arizeke Pharmaceuticals, Inc. | Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis |
US8524735B2 (en) * | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
ATE514793T1 (de) * | 2005-09-30 | 2011-07-15 | Centocor Ortho Biotech Inc | Zusammensetzungen und verfahren für il13- biomarker |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
US7993648B2 (en) * | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
AU2007259329A1 (en) * | 2006-05-12 | 2007-12-21 | Farris, Darise | Anthrax compositions and methods of use and production |
US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US9598488B2 (en) * | 2008-02-01 | 2017-03-21 | Albany Medical College | Blockage of interferon-gamma for prevention of polymicrobial synergy |
CA2739897C (en) | 2008-10-07 | 2017-10-03 | Mpex Pharmaceuticals, Inc. | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
US8629139B2 (en) * | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
BR112012004692B8 (pt) | 2009-09-04 | 2021-05-25 | Mpex Pharmaceuticals Inc | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano |
KR20150018765A (ko) * | 2012-01-20 | 2015-02-24 | 데니스 브라운 | 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도 |
JP6639228B2 (ja) * | 2012-03-29 | 2020-02-05 | アルター・バイオサイエンス・コーポレーション | 新生物を治療するための方法 |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
WO2014061016A1 (en) * | 2012-10-15 | 2014-04-24 | Yeda Research And Development Co. Ltd. | Use of sphingoid long chain bases and their analogs in treating and preventing bacterial infections |
WO2015066664A2 (en) * | 2013-11-04 | 2015-05-07 | Board Of Regents, The University Of Texas System | Compositions and methods for administration of an enzyme to a subject's airway |
SG11201605455YA (en) | 2014-01-10 | 2016-08-30 | Birdie Biopharmaceuticals Inc | Compounds and compositions for treating egfr expressing tumors |
WO2015168474A1 (en) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
AU2015286043B2 (en) | 2014-07-09 | 2020-08-20 | Birdie Biopharmaceuticals Inc. | Anti-PD-L1 combinations for treating tumors |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
WO2017156720A1 (zh) * | 2016-03-16 | 2017-09-21 | 谢彦晖 | 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
IL260690A (en) | 2018-07-19 | 2018-12-31 | Yeda Res & Dev | Sphingosine derivatives and their use against pulmonary bacterial infections |
EP4041276A4 (en) * | 2019-10-04 | 2024-02-07 | Univ Rutgers | TARGETED PULMONARY ADMINISTRATION COMPOSITIONS AND METHODS THEREOF |
CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
GB202105277D0 (en) * | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6072041A (en) * | 1996-06-03 | 2000-06-06 | Case Western Reserve University | Fusion proteins for protein delivery |
AU2001252970A1 (en) * | 2000-03-27 | 2001-10-08 | The Regents Of The University Of California | Ligands directed to the non-secretory component, non-stalk region of pIgR and methods of use thereof |
AU2002253889A1 (en) * | 2001-02-02 | 2002-10-03 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules |
-
2004
- 2004-01-09 AU AU2004204764A patent/AU2004204764A1/en not_active Abandoned
- 2004-01-09 WO PCT/US2004/000445 patent/WO2004062603A2/en active Application Filing
- 2004-01-09 EP EP04701216A patent/EP1589943A2/en not_active Withdrawn
- 2004-01-09 KR KR1020057012824A patent/KR20050114211A/ko not_active Application Discontinuation
- 2004-01-09 US US10/754,485 patent/US20050036951A1/en not_active Abandoned
- 2004-01-09 CA CA002512672A patent/CA2512672A1/en not_active Abandoned
- 2004-01-09 MX MXPA05007466A patent/MXPA05007466A/es not_active Application Discontinuation
-
2005
- 2005-07-07 IL IL169602A patent/IL169602A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004062603A2 (en) | 2004-07-29 |
IL169602A0 (en) | 2007-07-04 |
US20050036951A1 (en) | 2005-02-17 |
CA2512672A1 (en) | 2004-07-29 |
AU2004204764A1 (en) | 2004-07-29 |
KR20050114211A (ko) | 2005-12-05 |
EP1589943A2 (en) | 2005-11-02 |
WO2004062603A3 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05007466A (es) | Metodos para el tratamiento de enfermedades pulmonares. | |
IL228068A0 (en) | Antibodies specific to fcyriib and methods of using them | |
BRPI0408236A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
EP0923376A4 (en) | TREATMENT OF ASTHMA AND RESPIRATORY DISEASES | |
ZA200501128B (en) | Biphasic composition induced by polydextrose | |
TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
SE0203713D0 (sv) | Novel compounds | |
MXPA04000793A (es) | Novedoso metodo terapeutico. | |
WO2005115406A3 (en) | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents | |
WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
TW200407305A (en) | Novel compounds | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
WO2004091514A3 (en) | Cgrp receptor antagonists | |
WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
CY1110369T1 (el) | Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη | |
WO2005041864A3 (en) | Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method | |
MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
SE9900833D0 (sv) | Novel combination | |
CY1110368T1 (el) | Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη | |
SE9900834D0 (sv) | Novel combination | |
MXPA04003910A (es) | Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar. | |
WO2005097757A3 (en) | Nucleoside derivatives and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |